PMID- 34678905
OWN - NLM
STAT- MEDLINE
DCOM- 20211104
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 42
DP  - 2021 Oct 22
TI  - Amelioration of hypercalcemia by cinacalcet treatment in a subject with relapsing 
      acquired hypocalciuric hypercalcemia: A case report.
PG  - e27579
LID - 10.1097/MD.0000000000027579 [doi]
LID - e27579
AB  - RATIONALE: Hypocalciuric hypercalcemia is classified as acquired hypocalciuric 
      hypercalcemia (AHH) and familial hypocalciuric hypercalcemia (FHH). While FHH is 
      inherited as an autosomal dominant trait, AHH is one of the rare acquired 
      diseases and is usually treated with prednisolone. Here, we report a case with 
      relapsing AHH which was well controlled with cinacalcet therapy. PATIENT CONCERN: 
      A 68-year-old Japanese man was referred to our institution because of 
      hypercalcemia. Despite such hypercalcemia, he was almost asymptomatic. 
      DIAGNOSTICS: We diagnosed him as AHH due to the following reason. First, the 
      ratio of calcium (Ca)/creatinine clearance was very low which met the criteria. 
      Second, there was no overt family history of hypercalcemia. Third, his serum Ca 
      level was within the normal range 3 years before. Fourth, despite hypercalcemia, 
      he was almost asymptomatic and had no evidence of primary hyperparathyroidism. 
      INTERVENTIONS: Although it is known that steroid therapy is useful for AHH, 
      optimal treatment remains unknown and cinacalcet therapy is very much limited for 
      the treatment of AHH. In this subject, we introduced cinacalcet therapy for the 
      treatment of relapsing AHH. OUTCOMES: Serum Ca and parathyroid hormone levels 
      were normalized after such therapy with cinacalcet. CONCLUSIONS: We should bear 
      in mind that cinacalcet treatment is effective for the treatment of relapsing 
      AHH.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Sanada, Junpei
AU  - Sanada J
AD  - Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 
      Kurashiki, Japan.
FAU - Kamei, Shinji
AU  - Kamei S
FAU - Shimoda, Masashi
AU  - Shimoda M
FAU - Tatsumi, Fuminori
AU  - Tatsumi F
FAU - Kimura, Tomohiko
AU  - Kimura T
FAU - Obata, Atsushi
AU  - Obata A
FAU - Kohara, Kenji
AU  - Kohara K
FAU - Nakanishi, Shuhei
AU  - Nakanishi S
FAU - Kaku, Kohei
AU  - Kaku K
FAU - Mune, Tomoatsu
AU  - Mune T
FAU - Kaneto, Hideaki
AU  - Kaneto H
AUID- ORCID: 0000-0001-7898-1943
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Calcium-Regulating Hormones and Agents)
RN  - AYI8EX34EU (Creatinine)
RN  - UAZ6V7728S (Cinacalcet)
RN  - Hypocalciuric Hypercalcemia, Acquired
SB  - IM
MH  - Aged
MH  - Calcium-Regulating Hormones and Agents/*therapeutic use
MH  - Cinacalcet/*therapeutic use
MH  - Creatinine/blood
MH  - Humans
MH  - Hypercalcemia/*drug therapy
MH  - Male
PMC - PMC8542107
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2021/10/23 06:00
MHDA- 2021/11/05 06:00
PMCR- 2021/10/22
CRDT- 2021/10/22 20:55
PHST- 2021/07/28 00:00 [received]
PHST- 2021/10/07 00:00 [accepted]
PHST- 2021/10/22 20:55 [entrez]
PHST- 2021/10/23 06:00 [pubmed]
PHST- 2021/11/05 06:00 [medline]
PHST- 2021/10/22 00:00 [pmc-release]
AID - 00005792-202110220-00047 [pii]
AID - MD-D-21-05282 [pii]
AID - 10.1097/MD.0000000000027579 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Oct 22;100(42):e27579. doi: 
      10.1097/MD.0000000000027579.